The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist

S L Corson,F R Batzer,B Gocial,G Maislin

DOI: https://doi.org/10.1016/s0015-0282(16)55985-8

Abstract:Objective: To use a GnRH agonist (GnRH-a) to induce ovulation after priming with exogenous hMG. Design: Prospective, randomized double-blind protocol using one or two doses of intranasal nafarelin. Setting: Office-based ovulation induction program. PATIENTS, INTERVENTIONS: Infertile women not conceiving after use of clomiphene citrate for at least 6 months who were given hMG and nafarelin. No luteal support was given. Main outcome measures: Serum concentrations of FSH, LH, E2, and P acutely and at 6 days after GnRH-a administration. Duration of the luteal phase was assessed. Results: Ovulation with elevation of both FSH and LH was achieved. The two-dose regimen was more effective than one dose for sustained LH release. Luteal phase P values and luteal phase duration were both less than usually seen with gonadotropin hCG therapy in the absence of luteal phase support. Conclusions: Ovulation induction with GnRH-a after hMG priming produces unacceptable luteal phase cycles in the absence of hormonal support.